CN119746057A - 卡那吉努单抗的用途 - Google Patents

卡那吉努单抗的用途 Download PDF

Info

Publication number
CN119746057A
CN119746057A CN202411634666.2A CN202411634666A CN119746057A CN 119746057 A CN119746057 A CN 119746057A CN 202411634666 A CN202411634666 A CN 202411634666A CN 119746057 A CN119746057 A CN 119746057A
Authority
CN
China
Prior art keywords
antibody
nushan
patient
hscrp
kana
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411634666.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·希克
L·明德霍尔姆
J·普雷斯加德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN119746057A publication Critical patent/CN119746057A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202411634666.2A 2018-05-09 2018-08-24 卡那吉努单抗的用途 Pending CN119746057A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862669071P 2018-05-09 2018-05-09
US62/669,071 2018-05-09
PCT/IB2018/056455 WO2019215484A1 (en) 2018-05-09 2018-08-24 Use of canakinumab
CN201880094285.6A CN112584857A (zh) 2018-05-09 2018-08-24 卡那吉努单抗的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880094285.6A Division CN112584857A (zh) 2018-05-09 2018-08-24 卡那吉努单抗的用途

Publications (1)

Publication Number Publication Date
CN119746057A true CN119746057A (zh) 2025-04-04

Family

ID=63638190

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411634666.2A Pending CN119746057A (zh) 2018-05-09 2018-08-24 卡那吉努单抗的用途
CN201880094285.6A Pending CN112584857A (zh) 2018-05-09 2018-08-24 卡那吉努单抗的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880094285.6A Pending CN112584857A (zh) 2018-05-09 2018-08-24 卡那吉努单抗的用途

Country Status (12)

Country Link
US (1) US20210371511A1 (https=)
EP (1) EP3790576A1 (https=)
JP (2) JP2021523894A (https=)
KR (1) KR20210008847A (https=)
CN (2) CN119746057A (https=)
AU (1) AU2018422406A1 (https=)
BR (1) BR112020022576A2 (https=)
CA (1) CA3098277A1 (https=)
CL (1) CL2020002881A1 (https=)
MX (1) MX2020011909A (https=)
TW (1) TW201946652A (https=)
WO (1) WO2019215484A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402359A (zh) * 2020-11-04 2021-02-26 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
TR201802449T4 (tr) * 2005-10-26 2018-03-21 Novartis Ag Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.
MX362591B (es) * 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
BR112014007253A2 (pt) 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
WO2015084883A2 (en) * 2013-12-02 2015-06-11 Abbvie, Inc. Compositions and methods for treating osteoarthritis
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
UY37758A (es) * 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
JP2020524694A (ja) * 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
CN107723310B (zh) * 2017-10-19 2024-01-09 北京睿诚海汇健康科技有限公司 植物作为宿主在表达卡那抗体中的应用

Also Published As

Publication number Publication date
CN112584857A (zh) 2021-03-30
JP2021523894A (ja) 2021-09-09
BR112020022576A2 (pt) 2021-02-09
EP3790576A1 (en) 2021-03-17
WO2019215484A1 (en) 2019-11-14
CL2020002881A1 (es) 2021-05-14
KR20210008847A (ko) 2021-01-25
CA3098277A1 (en) 2019-11-14
US20210371511A1 (en) 2021-12-02
TW201946652A (zh) 2019-12-16
AU2018422406A1 (en) 2020-11-12
MX2020011909A (es) 2021-01-29
JP2023071904A (ja) 2023-05-23
JP7713983B2 (ja) 2025-07-28

Similar Documents

Publication Publication Date Title
JP6515168B2 (ja) Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
JP7805788B2 (ja) Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
JP2021503476A (ja) Ｉｌ−１７アンタゴニストを用いて化膿性汗腺炎を治療すること
RU2697383C2 (ru) Применение антагонистов il-17 для торможения прогрессирования структурных повреждений у пациентов с псориатическим артритом
US20150203592A1 (en) Compositions and methods for treating osteoarthritis
US20230331834A1 (en) Method of treating tendinopathy using interleukin-17 (il-17)
US20100273204A1 (en) Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
JP7713983B2 (ja) カナキヌマブの使用
JP2022513317A (ja) ｓｕＰＡＲならびに急性腎傷害の予測および治療
TW202434624A (zh) 治療或預防甲狀腺素運載蛋白調節之澱粉樣變性的方法
CN119546340A (zh) 使用白细胞介素-17（il-17）拮抗剂选择性治疗肌腱病的方法
CA3062179A1 (en) Methods of selectively treating asthma using il-17 antagonists
US20110104153A1 (en) Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
US20110053209A1 (en) Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
Morgado Internship Reports and Monograph Entitled “Pharmacokinetic Monitorization of Monoclonal Antibodies: The Example of Infliximab in Inflammatory Bowel Diseases”
JP2026507877A (ja) 化膿性汗腺炎（ｈｓ）を処置するための抗ｉｌ－３６ｒ抗体の使用
EA048127B1 (ru) Способ лечения воспалительного заболевания кишечника с применением комбинированной терапии антителами к ил-23 и фно-альфа
EA053045B1 (ru) Способ лечения воспалительного заболевания кишечника с применением комбинированной терапии антителами к ил-23 и фно-альфа
NZ624869A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
HK1181660A (en) Arthritis treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination